Navigation Links
Gen-Probe to Webcast Four Upcoming Investor Presentations
Date:9/3/2009

SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the following investor conferences:

  • Baird's 2009 Health Care Conference in New York at 2:45 p.m. Eastern Time (ET) on September 9.
  • Thomas Weisel Partners' Healthcare Conference 2009 in Boston at 9:45 a.m. ET on September 10.
  • The 2009 Morgan Stanley Global Healthcare Unplugged Conference in New York at 8:35 a.m. ET on September 14.
  • Think Equity's Sixth Annual Growth Conference in San Francisco at 1 p.m. ET on September 15.

These presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com. The webcasts will be available for 30 days following the events.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended June 30, 2009, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    Contact:

    Paula Izidoro
    Investor Relations
    858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Completes Acquisition of Tepnel Life Sciences
3. Gen-Probe to Webcast Two Upcoming Investor Presentations
4. Gen-Probe Borrows $170 Million Under New Line of Credit
5. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
6. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
8. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
9. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
10. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
11. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... 24, 2017  Driven by consumers, preference towards ... the fastest growing categories, finds the recently published ... Personal Care: Multi-regional Market Analysis and Opportunities ... firm Kline. "Biotechnology actives are derived ... more effective for skin and hair care applications," ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
Breaking Biology Technology:
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
Breaking Biology News(10 mins):